Generex Biotechnology Corporation, a development stage company, engages in the research, development, and commercialization of drug delivery systems and technologies for metabolic and immunological diseases. It develops a proprietary platform technology for the oral administration of large molecule drugs, including proteins, peptides, monoclonal antibodies, hormones, and vaccines. The company’s products include Generex Oral-lyn, an insulin spray formulation used for the treatment of Type-1 and Type-2 diabetes; Glucose RapidSpray, which provides an alternative for people who require additional glucose in their diet, as well as delivers glucose formulation directly into the mouth; BaBOOM! Energy Spray, an instant energy spray designed to increase energy levels for sports, work, study, travel, and overall fatigue; and Crave-NX, a fat-free glucose spray that is used as an aid for dieters. Generex Biotechnology Corporation’s under development products include medicinal chewing gum for the treatment of Type-2 diabetes mellitus and obesity; morphine and fentanyl products for breakthrough and postoperative pain; and AE37, an immunotherapeutic vaccine that is in Phase II clinical trials for patients with HER-2/neu positive breast cancer. The company markets its products through distributors and retail chains in Ecuador, Canada, and the United States. It has collaboration with Fertin Pharma A/S for the development of a metformin medicinal chewing gum.
- Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity.
- The Company’s proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company’s proprietary RapidMist™ device.
- The Company’s flagship product, Buccal insulin, which has been approved in India, Lebanon, Algeria, and Ecuador for the treatment of subjects with Type-1 and Type-2 diabetes, is in Phase III clinical trials at several sites around the world.
- Distribution Agreement for Generex Oral-lyn in Chile.
- Long-term marketing and distribution agreement for its glucose spray product with Merck S.A. de C.V. in Mexico.
- The Company is continuing its work toward developing synthetic vaccines for both pandemic and seasonal influenza strains.
- AE37 have the potential to completely change how breast cancer is treated. (according to Dr. Craig Eagle). AE37 as a preventative breast cancer vaccine should currently be valued over $1 billion.
Shares of Generex Biotechnology Corporation (NASDAQ:GNBT) skyrocketed 16% with heavy volume to $.54 cents per share after the company announced that it has entered into a sales agreement with Elias Shaker & Company, to represent Generex’s novel consumer products to national and regional retail and wholesale accounts in the USA.
At the current price there is plenty of room for growth for this corporation. As of today’s stock market you can buy 2 shares for about a dollar. A good long term investment considering the above facts.